Rapid COVID-19 lateral flow tests from Avacta and Mologic are expecting to displace the UK government’s reliance on tests from US company Innova in a major win for UK stocks.
According to reports, tests from Avacta and Mologic are set to be pivotal to the government’s plans to reopen the hospitality and entertainment sectors.
It is claimed that the test from Avacta is in its ‘final assessment’ stage from the Porton Down laboratory and it is speculated that the findings will be published in-line with Boris Johnson’s lockdown easing plans.
When approved, it is expected that the Avacta test will be available in ‘huge numbers’ from the start of April.
Moreover, the rapid test from Mologic is also firmly in the mix and the DHSC is awaiting assessment to confirm whether to approve both tests with Omega Diagnostics ready to produce these tests alongside Global Access Diagnostics.
Everyone’s a winner! The wait finally seems over for investors in Avacta and Omega Diagnostics
Investors in Avacta and Omega Diagnostics have been waiting for quite some time for the expectations to become a reality.
And this incredibly confident report from the HuffPost UK seems to suggest that investors in both stocks can hope for some fairly substantial and rewarding news in the coming week (s).
Elsewhere, Abingdon Health is also expected to be benefit through its role in the manufacture of the Avacta test. And Omega Diagnostics recently confirmed that it is lined-up to produce any test that is approved by the DHSC ( Colin King Q&A: Omega CEO discusses the significance of the DHSC contract ).
Everyone’s a winner it seems.